Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Teclegiorgis Gebremariam, Sondus Alkhazraji, Lin Lin, Nathan Wiederhold, Edward P. Garvey, William J. Hoekstra, Robert J. Schotzinger, Thomas F Patterson, Scott G. Filler, Ashraf S. Ibrahim

Research output: Contribution to journalArticle

8 Scopus citations


We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

Original languageEnglish (US)
Article numbere00390-17
JournalAntimicrobial Agents and Chemotherapy
Issue number9
Publication statusPublished - Sep 1 2017



  • Mucormycosis
  • Murine
  • Prophylaxis
  • Rhizopus arrhizus
  • VT-1161

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this